Amidst of COVID-19 outbreak, Infinium wishes to extend its support to the industry by offering 30% discount on its market research reports across all license formats.
Request Discount
Loading...
COVID-19! We are now including the impact analysis of the COVID-19 on Hydroxychloroquine Market report and the forecast period of this report shall be revised to 2020-2026. The section on the impact of COVID-19 on this market is included in the report for free. To know more Request a Sample of this report.

Hydroxychloroquine Market (Route of Administration - Oral, and Intravenous; Strength - 100 Mg, 250 Mg, and 500 Mg; Application - Rheumatoid Arthritis, Malaria, Covid-19, and Others): Global Industry Analysis, Trends, Size, Share and Forecasts to 2026

  • Published : May, 2020

  • Rep Id : HC0853

  • Category : Healthcare & Medical Devices

  • Status : Published

A recent report published by Infinium Global Research on hydroxychloroquine market provides in-depth analysis of segments and sub-segments in the global as well as regional hydroxychloroquine market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional hydroxychloroquine market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global hydroxychloroquine market. According to the report, the global hydroxychloroquine market is projected to grow at a healthy CAGR over the forecast period of 2020-2026.

 

Market Insight

Hydroxychloroquine is an anti-malarial prescription drug that has the capability to reduce fever and inflammation. The drug is mainly sold under the brand name Plaquenil among others. It is also used in lupus and arthritis patients as it helps in reducing pain, swelling and stiffness. Moreover, as the drug also has the ability to regulate the activity of the immune system, it is currently used in the treatment of COVID-19.

 

According to a number of studies, Hydroxychloroquine has shown strong antiviral effects on the coronavirus infection. Early clinical trial conducted in COVID-19 Chinese patients, showed that hydroxychloroquine had a significant effect, both in terms of clinical outcome and viral clearance. Moreover, it was one of the first potential agents to illustrate the ability to slow the SARS-CoV-2, the novel coronavirus, in a laboratory. This has prompted an increase in demand for the Hydroxychloroquine in the global markets for the treatment of COVID-19. Furthermore, as the number of patients affected by the COVID-19 pandemic is increasing globally, the demand for hydroxychloroquine is also expected to increase exponentially. In addition, in certain developing countries, malaria is on the rise, which will further increase the demand for Hydroxychloroquine over the future years. However, the continuous intake of Hydroxychloroquine causes side effects such as heart rhythm problems which is likely to have a negative impact on the Hydroxychloroquine market. Nonetheless, the ongoing clinical trials for the use of Hydroxychloroquine in infectious, immune, neo-plastic, and neurological diseases will generate new opportunities for the market growth.

 

Among the regions, North America will dominate the global market over the forecast years owing to the rising use of the drug for COVID-19 treatment. The U.S. is the world’s most affected country by coronavirus currently, by the number of cases, which has increased the demand for the drugs in the North America region. In recent times, India, the major producer of Hydroxychloroquine has exported 35.82 lakh tablets of the drug to the US along with nine metric tons of active pharmaceutical ingredient or API required in the manufacturing of the drug. However, Europe will hold the second-largest share as seven European countries are among the ten most affected countries with coronavirus. Furthermore, as more European countries are witnessing a surge in cases, the usage of Hydroxychloroquine is expected to intensify in Europe over 2020. Moreover, in the long term, the developing regions will emerge as the predominant users of Hydroxychloroquine due to the increasing cases of malaria in such countries

 

Segment Covered

The report on global hydroxychloroquine market covers segments such as route of administration, strength, and application. On the basis of route of administration, the sub-markets include oral, and intravenous. On the basis of strength, the sub-markets include 100 mg, 250 mg, and 500 mg. On the basis of application, the sub-markets include rheumatoid arthritis, malaria, covid-19, and others.

 

Companies Profiled:

The report provides profiles of the companies in the market such as Ipca Laboratories Ltd, Zydus Cadila, Novartis AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Rising Pharma Holdings Inc, Abcam plc, Mylan N.V., Abbott Laboratories, and Others.

 

Report Highlights:

The report provides deep insights into the demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of hydroxychloroquine market. Moreover, the study highlights current market trends and provides forecast from 2020-2026. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.


Other Reports in This Category
24 hour delivery through email
9923950043 Monday to Frieday 9am-7pm
looking for discount